AVANIR PHARMACEUTICALS (AVNR)

[Gd2Aussie3]

AVANIR Pharmaceuticals Schedules Conference Call to Discuss Phase III Results for Zenvia™ in Pseudobulbar Affect

ALISO VIEJO, Calif., August 10, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) plans to announce the top-line results from the confirmatory Phase III STAR trial of Zenvia in pseudobulbar affect (PBA) before market open on Tuesday, August 11, 2009. AVANIR management will host a conference call and webcast that same day at 5:00 a.m. Pacific time / 8:00 a.m. Eastern time to discuss the results of this clinical trial and answer questions.

The live call can be accessed by dialing [phone] for domestic callers and [phone] for international callers. The conference ID number is 24703376. A webcast of the live call can be accessed by visiting AVANIR's corporate website at www.avanir.com. To view the live webcast, please go to AVANIR's website prior to the start of the call to register, download and install the necessary software.

An archived copy of the webcast will be available on AVANIR's website for 7 days, and a telephone replay will be available through August 17, 2009, by dialing [phone] (domestic) or [phone] (international) and entering the conference ID number 24703376.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

AVANIR Investor Contacts
Eric Benevich
Brenna Mullen
949-389-6700
[e-mail]
or
Media Contacts:
Porter Novelli
Holli Dickson, 619-849-5380
[e-mail]
or
Kara DePolo, 619-849-5382
[e-mail]
-----------------------------------
G' day Mates,

Aussie